DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award
ID: 358726Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358726
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Therapeutic Idea Award (TIA) under the fiscal year 2025 Amyotrophic Lateral Sclerosis Research Program (ALSRP). This grant aims to support innovative, high-risk research proposals focused on drug or therapy development for Amyotrophic Lateral Sclerosis (ALS), with an emphasis on generating preliminary data for future therapeutic investigations. The program has a total funding amount of approximately $10.8 million, with individual awards capped at $600,000 and a performance period not exceeding two years. Interested applicants must submit pre-applications by June 6, 2025, and full applications by August 27, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    A03.pdf
    The Department of Defense's (DoD) FY25 Amyotrophic Lateral Sclerosis Research Program announces the Therapeutic Idea Award (TIA), which seeks innovative and high-risk research proposals aimed at drug or therapy development for Amyotrophic Lateral Sclerosis (ALS). The program has a total funding amount of approximately $10.8 million, with a cap of $600,000 per application and a performance period not exceeding two years. Pre-applications are due by June 6, 2025, and full applications by August 27, 2025. Eligible applicants include both extramural and intramural organizations, with independent investigators serving as Principal Investigators regardless of their career stage. The award prioritizes innovative research that produces preliminary data for therapeutic applications, focusing on drug discovery rather than solely pathophysiological studies. The application process involves a two-step submission of a pre-proposal and full proposal, evaluated through peer and programmatic reviews based on criteria such as innovation, impact, and research strategy. Projects should also develop relevant biomarkers for ALS treatment outcomes. Successful applications will align with the DoD mission to improve health for military Service Members and Veterans affected by ALS, ensuring advancements are relevant to these populations.
    Similar Opportunities
    Studies Addressing Rare Neurodegenerative Diseases including ALS
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity for studies addressing rare neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS). This grant aims to support research that advances the development of medical products intended to prevent, diagnose, mitigate, treat, or cure ALS and other rare neurodegenerative diseases in both adults and children. The initiative is crucial for addressing significant knowledge gaps in the field and is expected to have a substantial impact on the development of interventions for these conditions. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610 for further information. The FDA anticipates awarding approximately 10 grants in fiscal year 2025, with no cost-sharing or matching requirements.
    Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS)
    Centers for Disease Control and Prevention - ERA
    The Centers for Disease Control and Prevention (CDC) is inviting research proposals through a cooperative agreement to identify and evaluate potential risk factors for Amyotrophic Lateral Sclerosis (ALS). The opportunity encourages studies focusing on various aspects such as military service, contact sports, traumatic brain injury, neuroinflammation, and infectious agents, with four distinct funding options available to support both established and exploratory research. This initiative aims to enhance understanding of ALS risk factors, particularly in affected populations, and to analyze biological samples related to the Guamanian ALS cluster. Interested applicants can reach out to Dr. Candis Hunter at ncipcerpo@cdc.gov or by phone at 770-488-1347. The total estimated funding for this program is $7.5 million, with individual awards ranging from $0 to $500,000, and proposals are due by December 1, 2025, with awards expected to be announced by August 28, 2026.
    DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
    Tactical Behaviors for Autonomous Maneuver
    Dept of the Army -- Materiel Command
    The Department of the Army's Materiel Command is offering a funding opportunity through the Tactical Behaviors for Autonomous Maneuver Collaborative Research Program (TBAM-CRP) aimed at enhancing the capabilities of robotic and autonomous systems (RAS) for military operations in complex environments. This program seeks proposals that develop coordinated and adaptive behaviors for small groups of autonomous agents, focusing on innovative maneuver tactics and strategies to operate effectively in multi-domain operations against peer adversaries. The TBAM-CRP is critical for advancing military capabilities, leveraging new technologies in robotics and autonomous systems to improve situational awareness and operational effectiveness on the battlefield. Interested applicants, including institutions of higher education and for-profit organizations, are invited to submit proposals by April 24, 2024, with funding amounts ranging from $100,000 to $2.3 million available per award. For further inquiries, applicants can contact Christopher D. Justice at usarmy.adelphi.devcom-arl.mbx.tbam-crp-questions@army.mil.
    BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has announced a Broad Agency Announcement (BAA) for Extramural Biomedical and Human Performance Research and Development. This opportunity invites unrestricted applicants to submit proposals aimed at advancing biomedical research and development, with a focus on enhancing human performance. The program is critical for fostering innovation in science and technology, particularly in areas that support the Department of Defense's mission. The estimated total program funding is $10 million, with individual awards ranging from $750,000 to $50 million, and proposals are due by July 31, 2028. For further inquiries, applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    NFRP Outreach and Invitation for Response
    Dept. of the Army -- USAMRAA
    The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), is forecasting an opportunity for a Research-based Other Transactions Agreement (rOTA) under the Neurofibromatosis Research Program (NFRP). This initiative aims to accelerate the clinical translation of basic research related to neurofibromatosis (NF) by conducting collaborative Phase I and II clinical trials focused on promising therapeutic agents for NF1, NF2, and schwannomatosis. Historically, this requirement has been addressed through assistance agreements, and the government is now seeking feedback on this proposed approach, emphasizing the need for cost-sharing arrangements and access to patient populations. Interested parties can direct inquiries to Jason D. Kuhns at jason.d.kuhns.civ@mail.mil, with the opportunity being part of the FY21 portfolio and requiring a demonstrated history of collaborative research among participants.
    Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing drug repositioning and combination therapy development for Alzheimer's Disease (AD) and related dementias (ADRD). This initiative invites applications that utilize mouse models to conduct rigorous preclinical testing of FDA-approved drugs or investigational compounds, with the goal of establishing proof of concept for effective treatment strategies. Given the historical challenges in developing successful AD therapies, this program emphasizes a systematic approach and encourages collaboration between academia and industry to enhance research rigor and reproducibility. Applicants may receive up to $1 million annually, with a total funding pool of $6 million available for 4-5 awards. The application deadline is May 7, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced the "Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)." This program aims to support innovative research projects focused on Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), specifically targeting early-stage and diverse researchers who have not previously received significant NIH funding in this field. The initiative is designed to generate pilot data that can lead to larger funding applications, thereby enhancing research capabilities and workforce diversity in biomedical research. Grants of up to $100,000 per year for two years are available, with the application process opening on January 16, 2025, and the closing date set for March 16, 2026. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIH Director’s Transformative Research Awards (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to announce the NIH Director’s Transformative Research Awards, a federal grant opportunity aimed at supporting innovative and unconventional research projects. This program encourages individual scientists or collaborative teams to propose groundbreaking research that has the potential to redefine scientific paradigms or develop transformative technologies, without the need for preliminary data or detailed experimental plans. With an estimated total funding of $8 million and the expectation of awarding seven grants, interested applicants should prepare their proposals in advance, as applications will be solicited starting June 20, 2025, with a closing date of September 3, 2025. For further inquiries, potential applicants can contact Dr. Patricia Labosky at TransformativeAwards@mail.nih.gov or by phone at 301-594-4863.